Published • loading... • Updated
Other than Ozempic, Wall Street Now Focuses on Anti-Calvity. The 3 Companies to Monitor
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
One title has risen by 500% since February, another has more than doubled since the beginning of the year. But the company closest to the approval, with its productive heart in Italy, has lost almost half of its value. US Stock Exchange / Wall Street, First Floor
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
